8-K: Sight Sciences Reports Q1 2025 Financial Results and Reaffirms Full Year Revenue Guidance

Sight Sciences announced its Q1 2025 financial results, reporting a revenue decrease of 9% compared to the prior year, while reaffirming its full-year 2025 revenue guidance and improving adjusted operating expenses guidance.

Summary

• Sight Sciences reported a total revenue of $17.5 million for Q1 2025, a 9% decrease compared to the same period in the prior year.
• The Surgical Glaucoma segment experienced a 6% revenue decrease, totaling $17.1 million, primarily due to new Medicare LCDs restricting multiple MIGS procedures with cataract surgery.
• Dry Eye revenue decreased to $0.4 million from $1.0 million in the prior year, due to a focus on reimbursed TearCare procedures over cash pay procedures.
• The company's gross margin remained flat at 86% compared to the same period last year.
• Total operating expenses decreased by 7% to $29.0 million, mainly due to lower legal expenses.
• The net loss was $14.2 million, or $0.28 per share, compared to a net loss of $16.3 million, or $0.33 per share, in the same period last year.
• Cash and cash equivalents totaled $108.8 million as of March 31, 2025.
• Sight Sciences reaffirmed its full-year 2025 revenue guidance of $70.0 million to $75.0 million, representing a 6% to 12% decline compared to 2024.
• Adjusted operating expenses for full year 2025 are now expected to be $101.0 million to $105.0 million, an increase of 0% to 4% compared to 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue decreased, the company reaffirmed its full-year guidance and improved its adjusted operating expenses guidance. Management's comments are optimistic, but the challenges related to reimbursement and tariffs temper the overall outlook.

Positives

• Gross margin remained strong at 86%.
• Operating expenses decreased by 7% due to lower legal expenses.
• Net loss improved compared to the same period last year.
• The company launched OMNI Edge, building on the OMNI Surgical System.
• Adjusted operating expenses guidance improved to $101.0 million to $105.0 million.

Negatives

• Q1 2025 revenue decreased by 9% compared to the same period last year.
• Surgical Glaucoma revenue decreased by 6% due to Medicare LCD restrictions.
• Dry Eye revenue decreased significantly due to a shift in focus to reimbursed procedures.
• Cash used in the first quarter of 2025 totaled $11.6 million, compared to $10.8 million in the same period in the prior year, primarily due to higher annual cash incentive payments in the first quarter of 2025.

Risks

• The company faces risks related to changes in tariff policies impacting its products, as most are produced and assembled in China.
• Changes to reimbursement coverage and payment decisions for their products could impact revenue.
• The company is exposed to risks associated with disruptions to its supply chain.
• The new Medicare LCDs restricting multiple MIGS procedures performed with cataract surgery are expected to negatively impact revenue.

Future Outlook

Sight Sciences reaffirms its full-year 2025 revenue guidance of $70.0 million to $75.0 million and expects adjusted operating expenses of $101.0 million to $105.0 million.

Management Comments

• Paul Badawi, Co-Founder and Chief Executive Officer, stated that the team continues to execute well in a dynamic market environment and remains committed to serving interventional eyecare providers.
• Management believes consistent execution against strategic initiatives will make 2025 a transformational year for the business.

Industry Context

The announcement highlights the challenges faced by medical device companies due to changes in reimbursement policies (Medicare LCDs) and the impact of tariffs on products manufactured in China. The company is focusing on expanding market access for its TearCare product and driving awareness of interventional procedures for glaucoma and dry eye.

Comparison to Industry Standards

• The company's gross margin of 86% is relatively high compared to some medical device companies, suggesting a strong pricing power or efficient cost management.
• Companies like Alcon and Johnson & Johnson Vision also operate in the eyecare market, but Sight Sciences focuses on interventional technologies, differentiating it from companies primarily focused on pharmaceuticals or traditional surgical devices.
• The impact of Medicare LCDs on MIGS procedures is a common challenge for companies in the glaucoma surgery space, requiring them to adapt their commercial strategies and focus on alternative market segments.

Stakeholder Impact

• Shareholders may be concerned about the revenue decrease but reassured by the reaffirmed guidance and improved expense management.
• Employees may be affected by the company's efforts to control expenses.
• Customers (eyecare providers) will be interested in the launch of OMNI Edge and the company's efforts to secure reimbursement for TearCare.
• Patients may benefit from the company's focus on interventional technologies for glaucoma and dry eye.

Next Steps

• The company plans to continue building commercial momentum in MIGS.
• Sight Sciences will focus on establishing equitable reimbursement for TearCare.
• The company will continue publishing new clinical and economic data.
• Sight Sciences will advance its robust product pipeline.
• The company will engage with accounts post LCD clarity with restrictions on multiple MIGS.
• Sight Sciences will certify new OMNI surgeons.
• The company will continue to develop the standalone pseudophakic MIGS segment.
• Sight Sciences will develop international markets.
• The company will grow the commercial team and expand adoption and usage of its products.

Key Dates

Keywords

Sight Sciences, Financial Results, Revenue Guidance, Glaucoma, Dry Eye, MIGS, TearCare, OMNI, Operating Expenses, Medicare LCDs